Preventing Opioid Use Disorder in Homeless Youth
This study is looking for young people (ages 14-24) who are experiencing homelessness and may be at risk for opioid use disorder (OUD) or have mental health challenges. The goal is to find the best ways to help prevent OUD and improve mental health in this group. You might receive one of three behavioral support programs: Motivational Interviewing/Community Reinforcement Approach (MI/CRA), Strengths-Based Outreach and Advocacy (SBOA), or a combination of both. Some participants will receive standard services (Services as Usual). Researchers will check your substance use and mental health over 24 months to see which approaches work best. The study is currently recruiting 300 participants.
- Study design
- This is an interventional study comparing different behavioral support programs. It plans to enroll 300 participants.
- What's involved
- You would participate in behavioral sessions, which could be two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions, or a flexible number of Strengths-Based Outreach and Advocacy sessions. You would also have interviews and drug tests at baseline, and then at 3, 6, 12, 18, and 24 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 24 months after the intervention, with assessments at 3, 6, 12, 18, and 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness
At a glance
Conditions
Where it's being run
2 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Form 90 Substance Use interviewAdministered at baseline, and 3-, 6-, and 12-, 18-, and 24-months post intervention.
Self-reported interviewer-administered Form 90 Substance Use interview developed for National Institute on Alcohol Abuse and Alcoholism (NIAAA) funded Project Match. The Form 90 differentiates illicit drug use from prescribed drug use including marijuana.
- Shortened Inventory of Problems - Alcohol and Drugs (SIP-AD)Administered at baseline, and 3-, 6-, and 12-, 18-, and 24-months post intervention.
The SIP-AD measures consequences related to impulse control and social responsibility, as well as physical, interpersonal, and intrapersonal domains with good psychometric properties.
- Presence of drugs of abuseAdministered at baseline, and 3-, 6-, and 12-, 18-, and 24-months post intervention.
One-step BMC ToxCup® Urine Test Kit Provides instant reading urine test for the presence or lack of detection of cannabinoids, amphetamines, methamphetamines, phencyclidine (PCP), cocaine/crack, and opiates. (Branan Medical Corp., Irvine, CA). Detection levels: Marijuana 50 ng/ml Cocaine 150 ng/ml Opiates 300 ng/ml Methamphetamine 500 ng/ml Ecstasy 500 ng/ml Phencyclidine 25 ng/ml Propoxyphene 300 ng/ml Benzodiazepines 300 ng/ml Barbiturates 300 ng/ml Methadone 300 ng/ml Buprenorphine 10 ng/ml Tricyclic Antidepressants 1000 ng/ml Oxycodone 100 ng/ml
- Beck Depression Inventory II (BDI-II)Administered at baseline, and 3-, 6-, and 12-, 18-, and 24-months post intervention.
The most frequently used self-report instrument to assess mood, cognitive and somatic aspects of depression. The BDI-II has good psychometric properties. Scores range from 0 - 63 with higher scores indicating more depressived symptoms and worse outcomes.
- Beck Anxiety Inventory (BAI)Administered at baseline, and 3-, 6-, and 12-, 18-, and 24-months post intervention.
Used to assess current anxiety symptoms via 21 items, rated in intensity with scores ranging from 0-63. It was developed to discriminate symptoms of anxiety from depressive symptoms, and has alpha coefficients ranging from 0.90-0.94. Higher scores indicate more anxiety symptoms and worse outcomes.
- Short Form-12Administered at baseline, and 3-, 6-, and 12-, 18-, and 24-months post intervention.
Standardized, internationally used instrument that provides a general measure of health status.The 12 items on the SF-12 are summarized in two weighted summary scales, and generate a mental health and physical health score. Scores range from 1 -100. Lower scores indicate poorer health. Construct validity has been evaluated with adult users of a homeless day shelter